Complications of biologic therapy for pediatric cancer - What the surgeon needs to know

Area of Science:

• Oncology
• Surgical Oncology
• Pharmacology

Background:

• Biologic therapy has emerged as a significant treatment modality in pediatric oncology over the last 20 years.
• Advances in tumor sequencing have identified targetable mutations, driving the development of novel biologic agents.
• Increased use of these agents necessitates greater awareness among surgeons regarding potential complications.

Purpose of the Study:

• To highlight the growing importance of biologic agents in pediatric cancer treatment.
• To inform surgeons about potential complications associated with biologic therapies.
• To emphasize the need to weigh the risks and benefits of biologic agents in treatment strategies.

Main Methods:

• Review of current literature on biologic therapies in pediatric oncology.
• Analysis of known complications associated with biologic agents.
• Discussion of the surgical implications and management of these complications.

Main Results:

• Biologic agents offer targeted treatment options for pediatric cancers based on tumor genetic profiles.
• Complications can be direct (e.g., gastrointestinal perforation, pneumothorax) or indirect (e.g., surgical wound healing issues).
• The morbidity associated with these complications requires careful consideration.

Conclusions:

• Surgeons must be vigilant in identifying and managing complications arising from biologic cancer therapies.
• The potential benefits of biologic agents must be carefully weighed against their associated risks and morbidities.
• Integrating awareness of biologic agent complications into surgical practice is crucial for optimizing pediatric cancer care.